Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth And Santaris To Collaborate On RNA Antagonists

This article was originally published in The Pink Sheet Daily

Executive Summary

Danish biotech gets $7 million upfront, $10 million equity investment in Locked Nucleic Acid platform licensing agreement.

You may also be interested in...



Pfizer Expands Santaris Deal to Boost Presence in RNA-Targeted Drug Development

RNA-targeted medicines receive a boost from Pfizer's expansion of its strategic alliance with Danish firm Santaris

Pfizer Expands Santaris Deal to Boost Presence in RNA-Targeted Drug Development

RNA-targeted medicines receive a boost from Pfizer's expansion of its strategic alliance with Danish firm Santaris

Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals

"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel